An Update to the Pilot Study of 177Lu-PSMA in Low Volume Hormone-Sensitive Prostate Cancer
Bastiaan M. Privé, Stijn Muselaers, Inge M. van Oort, Marcel J. R. Janssen, Steffie M. B. Peters, Willemijn A. M. van Gemert, Maike J.M. Uijen, Melline M. G. Schilham, J.P. Michiel Sedelaar, Harm Westdorp, Niven Mehra, Martin Gotthardt, Jelle O. Barentsz, Winald R. Gerritsen, J.A. Witjes, James Nagarajah
Abstract
177 Lu-PSMA-617 radioligand therapy is a novel treatment for end-stage prostate cancer, which could also be applied to patients with hormone-sensitive prostate cancer with high expression levels of prostate-specific membrane antigen (PSMA). In this perspective, we review the recent results of toxicity, radiation doses, and treatment effect of 177 Lu-PSMA in patients with low volume metastatic hormone-sensitive prostate cancer. Moreover, we present long-term follow-up data, such as toxicity and time without androgen deprivation therapy (ADT), of the patients who participated in this trial. Overall, 177 Lu-PSMA appeared to be a feasible and safe treatment modality in this setting, as well as in long-term follow-up. We observed that men with a prostate-specific antigen (PSA) response of more than 50% seemed to especially benefit from this therapy by postponing ADT and thus preserving the quality of life.